Krystal Biotech Reports Promising Results for KB707 Trial

Krystal Biotech ( (KRYS) ) just unveiled an update.

On June 2, 2025, Krystal Biotech presented a clinical update on its Phase 1/2 trial of inhaled KB707, a novel HSV-based immunotherapy for advanced lung tumors, at the ASCO Annual Meeting. The study showed that KB707 was safe, well-tolerated, and demonstrated promising anti-tumor effects, with a 36% objective response rate in heavily pre-treated non-small cell lung cancer patients. The results suggest potential synergy with immune checkpoint inhibitors, and further evaluation is ongoing.

The most recent analyst rating on (KRYS) stock is a Buy with a $208.00 price target. To see the full list of analyst forecasts on Krystal Biotech stock, see the KRYS Stock Forecast page.

Spark’s Take on KRYS Stock

According to Spark, TipRanks’ AI Analyst, KRYS is a Outperform.

Krystal Biotech’s strong financial performance and positive earnings call are key strengths, supported by revenue growth and strategic expansions. However, technical analysis indicates a bearish trend, and the valuation appears high, presenting potential risks. The company’s ability to manage these challenges and maintain growth will be crucial for future stock performance.

To see Spark’s full report on KRYS stock, click here.

More about Krystal Biotech

Krystal Biotech, Inc. operates in the biotechnology industry, focusing on developing novel gene therapies. The company specializes in creating innovative treatments for dermatological and respiratory conditions, with a particular emphasis on utilizing herpes simplex virus (HSV)-based vectors for therapeutic delivery.

Average Trading Volume: 339,218

Technical Sentiment Signal: Sell

Current Market Cap: $3.64B

For an in-depth examination of KRYS stock, go to TipRanks’ Stock Analysis page.